Managing Partner, Montreal and Munich
Dr. Birner is responsible for TVM Capital Life Science’s overall investment strategy and fund operations in North America and Europe. He also serves as a member of the fund advisory board of TVM Capital Life Science’s China BioPharma Capital I fund.
Dr. Birner joined TVM Capital in 2000 as an investment manager. He currently serves as Chairman of the board of directors of Noxxon Pharma N.V., SpePharm Holdings BV, leon nanodrugs GmbH, Argos Therapeutics and AL-S Pharma AG. He is also a member of the board of directors of Proteon Therapeutics Inc. and Acer Therapeutics Inc. Dr. Birner previously served on the board of directors of Horizon Pharma, Inc., Bioxell SA, Evotec AG, Probiodrug AG and Jerini AG. Prior to his current tenure, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development.
Before starting his professional career in business, he earned substantial academic merits, including a position as Assistant Professor for biochemistry at the Ludwig-Maximilian-University (LMU), following his summa cum laude doctoral degree in biochemistry at LMU; his doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner also holds an MBA from Harvard Business School.